GTx Company Profile (NASDAQ:GTXI)

About GTx (NASDAQ:GTXI)

GTx logoGTx, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs). Its lead product candidate, enobosarm (GTx-024), had been evaluated in over 24 completed or ongoing clinical trials, including in approximately six Phase II and two Phase III clinical trials. The Company is also engaged in the development of GTx-758 (Capesaris), an oral nonsteroidal selective estrogen receptor alpha agonist, for secondary hormonal therapy in men with metastatic and high-risk non-metastatic castration resistant prostate cancer (CRPC). Its product candidate, Enobosarm, for the treatment of women with advanced androgen receptor (AR) positive triple-negative breast cancer (TNBC), is in Phase II clinical development-stage.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:GTXI
  • CUSIP: 40052B10
  • Web: www.gtxinc.com
Capitalization:
  • Market Cap: $127.18 million
  • Outstanding Shares: 16,058,000
Average Prices:
  • 50 Day Moving Avg: $7.99
  • 200 Day Moving Avg: $5.68
  • 52 Week Range: $2.73 - $9.90
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.83
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.53 per share
  • Price / Book: 14.94
Profitability:
  • EBITDA: ($26,470,000.00)
  • Return on Equity: -192.51%
  • Return on Assets: -145.17%
Debt:
  • Current Ratio: 2.60%
  • Quick Ratio: 2.60%
Misc:
  • Average Volume: 32,855 shs.
  • Beta: 1.6
  • Short Ratio: 8.54
 

Frequently Asked Questions for GTx (NASDAQ:GTXI)

What is GTx's stock symbol?

GTx trades on the NASDAQ under the ticker symbol "GTXI."

How were GTx's earnings last quarter?

GTx, Inc. (NASDAQ:GTXI) released its earnings results on Monday, August, 14th. The company reported ($0.40) EPS for the quarter. View GTx's Earnings History.

Who are some of GTx's key competitors?

Who are GTx's key executives?

GTx's management team includes the folowing people:

  • Robert James Wills Ph.D., Executive Chairman of the Board
  • Marc S. Hanover, Chief Executive Officer, Director
  • Jason T. Shackelford, Senior Director, Accounting and Corporate Controller, and Principal Financial and Accounting Officer
  • Henry P. Doggrell Sr., Vice President, Chief Legal Officer, Secretary
  • Diane C Young M.D., Vice President, Chief Medical Officer
  • Joseph R. Hyde III, Lead Director
  • Garry Neil M.D., Director
  • Michael G. Carter M.D., Independent Director
  • J. Kenneth Glass, Independent Director
  • Kenneth S. Robinson M.D., Independent Director

Who owns GTx stock?

GTx's stock is owned by many different of retail and institutional investors. Top institutional shareholders include HYDE JOSEPH R III (38.50%) and PYRAMID PEAK FOUNDATION (29.52%). Company insiders that own GTx stock include J Kenneth Glass, Marc Steven Hanover, Peak Foundation Pyramid and Robert James Wills. View Institutional Ownership Trends for GTx.

How do I buy GTx stock?

Shares of GTx can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GTx's stock price today?

One share of GTx stock can currently be purchased for approximately $7.92.


MarketBeat Community Rating for GTx (NASDAQ GTXI)
Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  87 (Vote Outperform)
Underperform Votes:  91 (Vote Underperform)
Total Votes:  178
MarketBeat's community ratings are surveys of what our community members think about GTx and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for GTx (NASDAQ:GTXI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for GTx (NASDAQ:GTXI)
Price Target History for GTx (NASDAQ:GTXI)
Analysts' Ratings History for GTx (NASDAQ:GTXI)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/9/2016Jefferies Group LLCReiterated RatingHold$1.00N/AView Rating Details
(Data available from 10/20/2015 forward)

Earnings

Earnings History for GTx (NASDAQ:GTXI)
Earnings by Quarter for GTx (NASDAQ:GTXI)
Earnings History by Quarter for GTx (NASDAQ GTXI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/14/2017Q2 2017($0.40)ViewN/AView Earnings Details
5/15/2017Q1 2017($0.39)ViewN/AView Earnings Details
3/15/2017Q4 2016($0.57)($0.44)ViewN/AView Earnings Details
11/3/2016Q3($0.05)($0.05)ViewN/AView Earnings Details
8/9/2016Q2($0.05)($0.04)ViewN/AView Earnings Details
5/10/2016Q1($0.04)$0.01ViewN/AView Earnings Details
3/3/2016Q415($0.10)($0.04)ViewListenView Earnings Details
10/29/2015Q315($0.06)($0.04)ViewListenView Earnings Details
8/6/2015Q215($0.04)($0.03)ViewListenView Earnings Details
5/8/2015Q1($0.04)($0.04)ViewListenView Earnings Details
3/4/2015Q314($0.07)($0.05)ViewListenView Earnings Details
11/10/2014Q214($0.10)($0.06)ViewListenView Earnings Details
8/5/2014Q2($0.11)($0.15)ViewN/AView Earnings Details
5/8/2014Q114($0.12)($0.14)ViewN/AView Earnings Details
3/4/2014Q413($0.13)($0.12)ViewListenView Earnings Details
11/12/2013Q313($0.21)($0.14)ViewListenView Earnings Details
7/19/2013Q2 2013($0.22)($0.20)ViewN/AView Earnings Details
5/3/2013Q1 2013($0.21)($0.20)ViewListenView Earnings Details
2/21/2013Q4 2012($0.21)($0.17)ViewListenView Earnings Details
11/8/2012Q312($0.17)$0.12$1.93 millionViewN/AView Earnings Details
8/8/2012($0.17)($0.17)ViewN/AView Earnings Details
5/8/2012($0.17)($0.18)ViewN/AView Earnings Details
2/21/2012($0.17)($0.17)ViewN/AView Earnings Details
11/4/2011($0.18)($0.15)ViewN/AView Earnings Details
8/9/2011($0.19)($0.21)ViewN/AView Earnings Details
5/9/2011($0.13)($0.05)ViewN/AView Earnings Details
2/24/2011($0.16)($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for GTx (NASDAQ:GTXI)
Current Year EPS Consensus Estimate: $-1.16 EPS
Next Year EPS Consensus Estimate: $-1.16 EPS

Dividends

Dividend History for GTx (NASDAQ:GTXI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for GTx (NASDAQ:GTXI)
Insider Ownership Percentage: 41.20%
Institutional Ownership Percentage: 9.01%
Insider Trades by Quarter for GTx (NASDAQ:GTXI)
Institutional Ownership by Quarter for GTx (NASDAQ:GTXI)
Insider Trades by Quarter for GTx (NASDAQ:GTXI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/14/2016Peak Foundation PyramidMajor ShareholderBuy7,716,049$0.81$6,249,999.69View SEC Filing  
6/16/2016Robert James WillsChairmanBuy100,000$0.65$65,000.00View SEC Filing  
3/1/2016J Kenneth GlassDirectorBuy44,000$0.60$26,400.00View SEC Filing  
1/26/2016Marc Steven HanoverCEOBuy4,000$0.65$2,600.00View SEC Filing  
1/25/2016Marc Steven HanoverCEOBuy12,813$0.63$8,072.19View SEC Filing  
1/19/2016Marc Steven HanoverCEOBuy25,000$0.50$12,500.00View SEC Filing  
1/14/2016Marc Steven HanoverCEOBuy25,000$0.49$12,250.00View SEC Filing  
12/24/2015J Kenneth GlassDirectorBuy100$0.79$79.00View SEC Filing  
12/22/2015J Kenneth GlassDirectorBuy1,907$0.78$1,487.46View SEC Filing  
12/21/2015J Kenneth GlassDirectorBuy39,900$0.78$31,122.00View SEC Filing  
5/19/2015J Kenneth GlassDirectorBuy24,500$1.25$30,625.00View SEC Filing  
5/14/2015Robert James WillsChairmanBuy46,140$0.96$44,294.40View SEC Filing  
5/8/2015Henry Patton DoggrellVPBuy25,477$0.80$20,381.60View SEC Filing  
5/8/2015Robert James WillsChairmanBuy50,000$0.80$40,000.00View SEC Filing  
4/22/2015J Kenneth GlassDirectorBuy10,000$0.72$7,200.00View SEC Filing  
4/21/2015J Kenneth GlassDirectorBuy11,608$0.71$8,241.68View SEC Filing  
4/15/2015J Kenneth GlassDirectorBuy3,300$0.72$2,376.00View SEC Filing  
4/10/2015J Kenneth GlassDirectorBuy16,400$0.67$10,988.00View SEC Filing  
9/23/2014Marc Steven HanoverCEOBuy5,000$0.75$3,750.00View SEC Filing  
9/17/2014Marc Steven HanoverCEOBuy10,000$0.74$7,400.00View SEC Filing  
8/21/2014Marc Steven HanoverCEOBuy20,000$1.00$20,000.00View SEC Filing  
8/19/2014Marc Steven HanoverCEOBuy10,000$1.01$10,100.00View SEC Filing  
8/8/2014Henry Patton DoggrellVPBuy10,000$0.97$9,700.00View SEC Filing  
8/8/2014Marc Steven HanoverCEOBuy30,000$0.93$27,900.00View SEC Filing  
8/7/2014Jason T ShackelfordInsiderBuy10,000$0.92$9,200.00View SEC Filing  
8/7/2014Marc Steven HanoverCEOBuy30,000$0.92$27,600.00View SEC Filing  
6/6/2014James T DaltonVPSell72,883$1.30$94,747.90View SEC Filing  
3/21/2014Jack Schulermajor shareholderSell1,192,251$1.84$2,193,741.84View SEC Filing  
8/22/2013Jack Schulermajor shareholderBuy93,777$1.36$127,536.72View SEC Filing  
8/21/2013Jack Schulermajor shareholderBuy309,591$1.42$439,619.22View SEC Filing  
7/9/2013Mark Edward MostellerCFOSell17,000$6.99$118,830.00View SEC Filing  
1/17/2013James T DaltonVPSell20,000$5.20$104,000.00View SEC Filing  
12/14/2012Timothy R G SearDirectorBuy50,000$4.33$216,500.00View SEC Filing  
8/27/2012J Kenneth GlassDirectorBuy10,000$3.76$37,600.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for GTx (NASDAQ:GTXI)
Latest Headlines for GTx (NASDAQ:GTXI)
Source:
DateHeadline
americanbankingnews.com logoAnalyzing GTx (GTXI) & Blueprint Medicines Corporation (BPMC)
www.americanbankingnews.com - October 8 at 6:16 PM
reuters.com logoBRIEF-Aisling capital IV LP reports 6.2 pct passive stake in GTX as of Sept 29
www.reuters.com - October 7 at 12:50 AM
globenewswire.com logoGO Therapeutics appoints Dr. Robert J. Wills to Board of Directors
globenewswire.com - October 5 at 2:31 PM
thestreet.com logoGTx Announces Closing Of $48.5 Million Private Placement
www.thestreet.com - September 29 at 4:37 PM
reuters.com logoBRIEF-GTx announces $48.5 million private placement
www.reuters.com - September 27 at 5:14 PM
bizjournals.com logoMemphis drug developer announces $48.5 private placement
www.bizjournals.com - September 27 at 5:14 PM
finance.yahoo.com logoGTx Announces Webcast of Corporate Presentation at the 2017 Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 26 at 11:23 AM
businesswire.com logoGTx to Host Key Opinion Leader Luncheon on the Topic of Stress Urinary Incontinence on September 28 th in New York City
www.businesswire.com - September 23 at 6:50 PM
finance.yahoo.com logoGTx to Host Key Opinion Leader Luncheon on the Topic of Stress Urinary Incontinence on September 28th in New York City
finance.yahoo.com - September 22 at 1:17 PM
americanbankingnews.com logoGTx (GTXI) vs. Its Peers Financial Comparison
www.americanbankingnews.com - September 19 at 12:48 AM
americanbankingnews.com logoComparing GTx (GTXI) and Its Peers
www.americanbankingnews.com - September 16 at 6:30 PM
streetinsider.com logoGTx, Inc. (GTXI) Reports ositive Results from Enobosarm Phase 2 Proof-of-Concept Clinical Trial in Women with SUI
www.streetinsider.com - September 14 at 7:58 PM
finance.yahoo.com logoGTx's (GTXI) Enobosarm Positive in Phase II, Shares Down
finance.yahoo.com - September 14 at 7:58 PM
finance.yahoo.com logoGTx's (GTXI) Enobosarm Positive in Phase II, Shares Down
finance.yahoo.com - September 14 at 7:58 PM
finance.yahoo.com logoGTx Announces Positive Results from Enobosarm Phase 2 Proof-of-Concept Clinical Trial in Women with Stress Urinary Incontinence
finance.yahoo.com - September 14 at 4:00 AM
americanbankingnews.com logoGTx, Inc. (GTXI) Releases Earnings Results
www.americanbankingnews.com - August 15 at 1:10 PM
finance.yahoo.com logoGTx Provides Corporate Update and Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 14 at 7:38 PM
finance.yahoo.com logoGTx reports 2Q loss
finance.yahoo.com - August 14 at 7:38 PM
bizjournals.com logoAstellas Head of Medical Affairs Americas Shontelle Dodson Joins National Pharmaceutical Council Board of Directors
www.bizjournals.com - July 14 at 2:49 AM
finance.yahoo.com logoGTx Discusses Key Goals with WSA
finance.yahoo.com - July 12 at 7:59 PM
zacks.com logoGTx's (GTXI) Enobosarm Positive in Phase II Study; Shares Up
www.zacks.com - June 15 at 12:03 AM
seekingalpha.com logoVeru Healthcare: The Merger And What Lies Ahead
seekingalpha.com - June 13 at 11:09 AM
baystreet.ca logoGTx Hikes on Treatment Test Results
www.baystreet.ca - June 13 at 11:09 AM
streetinsider.com logoGTx, Inc. (GTXI) Releases Preliminary Results from Ongoing Phase 2 Proof-of-Concept Clinical Trial in Women with SUI
www.streetinsider.com - June 13 at 11:09 AM
rttnews.com logoGTx Inc. (GTXI) Jumped To A 4-Month High On Study Results
www.rttnews.com - June 13 at 11:09 AM
feeds.benzinga.com logoMid-Day Market Update: Crude Oil Up 1%; GTx Shares Spike Higher
feeds.benzinga.com - June 12 at 12:43 PM
seekingalpha.com logoGTx's enobosarm shows treatment effect in mid-stage study in postmenopausal women with stress urinary incontinence; shares up 14% premarket
seekingalpha.com - June 12 at 8:28 AM
bizjournals.com logoDrugmakers and biotechs increasingly view Trump as a business risk
www.bizjournals.com - May 19 at 10:06 AM
bizjournals.com logoBiotech firms increasingly view Trump as a business risk
www.bizjournals.com - May 17 at 5:34 PM
reuters.com logoBRIEF-GTX reports Q1 net loss per share of $0.39
www.reuters.com - May 16 at 11:27 AM
businesswire.com logoGTx Announces Acceptance of an Abstract on Preliminary Results from Phase 2 Clinical Trial in Women with Stress Urinary Incontinence at the International Continence Society ...
www.businesswire.com - May 12 at 6:14 PM
streetinsider.com logoGTx, Inc. (GTXI) Reports Preclinical Study Results of SARMs in DMD Models Published in Human Molecular Genetics
www.streetinsider.com - May 3 at 3:03 PM
us.rd.yahoo.com logoGTx Provides Corporate Update and Reports Fourth Quarter and Year-End 2016 Financial Results
us.rd.yahoo.com - March 16 at 3:56 AM
biz.yahoo.com logoQ4 2016 GTX Inc Earnings Release - Before Market Open
us.rd.yahoo.com - March 16 at 3:56 AM
baystreet.ca logoGTx (GTXI) Dips on Quarterly Loss
www.baystreet.ca - March 15 at 5:54 PM
reuters.com logoBRIEF-Gtx Inc qtrly loss per share $0.44
www.reuters.com - March 15 at 5:54 PM
seekingalpha.com logoGTx beats by $0.13
seekingalpha.com - March 15 at 7:32 AM
biz.yahoo.com logoGTX INC /DE/ Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - January 14 at 4:46 AM
biz.yahoo.com logoGTX INC /DE/ Files SEC form 8-K, Other Events
us.rd.yahoo.com - December 21 at 11:30 PM
streetinsider.com logoJefferies Cuts Price Target on GTx, Inc. (GTXI) to $7 Following Enobosarm Trial Results
www.streetinsider.com - December 9 at 10:14 AM
streetinsider.com logoGTx, Inc. (GTXI) Announces Early Initial Success from Ongoing Enobosarm Phase 2 in ER+/AR+ Breast Cancer
www.streetinsider.com - December 8 at 11:14 PM
us.rd.yahoo.com logoGTx Reports Results from Ongoing Enobosarm Phase 2 Clinical Trial in ER+/AR+ Breast Cancer
us.rd.yahoo.com - December 8 at 10:53 AM
investopedia.com logoGTx Announces 1-For-10 Reverse Stock Split (GTXI)
www.investopedia.com - December 7 at 10:35 AM
biz.yahoo.com logoGTX INC /DE/ Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statement
biz.yahoo.com - December 6 at 10:40 AM
investopedia.com logoGTx Declares 1-For-10 Reverse Stock Split (GTXI)
www.investopedia.com - December 6 at 10:40 AM
us.rd.yahoo.com logoEnobosarm Meets Pre-Specified Primary Efficacy Endpoint in Ongoing Phase 2 Clinical Trial in ER+/AR+ Breast Cancer
us.rd.yahoo.com - November 29 at 4:55 PM
us.rd.yahoo.com logoEnobosarm Meets Pre-Specified Primary Efficacy Endpoint in Ongoing Phase 2 Clinical Trial in ER+/AR+ Breast Cancer
us.rd.yahoo.com - November 29 at 4:55 PM
us.rd.yahoo.com logo7:04 am GTX announces that enobosarm achieved the pre-specified primary efficacy endpoint in both stage 1 and the ongoing stage 2 of its Phase 2 clinical trial in women with ER+,AR+ breast cancer
us.rd.yahoo.com - November 29 at 4:55 PM
us.rd.yahoo.com logo7:04 am GTX announces that enobosarm achieved the pre-specified primary efficacy endpoint in both stage 1 and the ongoing stage 2 of its Phase 2 clinical trial in women with ER+,AR+ breast cancer
us.rd.yahoo.com - November 29 at 4:55 PM
businesswire.com logoBusiness Wire Information
www.businesswire.com - November 23 at 8:00 AM

Social

Chart

GTx (GTXI) Chart for Friday, October, 20, 2017

This page was last updated on 10/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.